Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Data Show Increased Cancer-Related Mortality in Incarcerated Population

November 19, 2025
By Cary Gross, MD
Commentary
Video

A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.

A longitudinal study published in JAMA NetworkOpen sought to explore quality of care among patients who are incarcerated or recently released and compare their outcomes with those of the general population.1 One of the study authors, Cary P. Gross, MD, discussed the background for this study in an interview with CancerNetwork®.

Gross, professor of General Medicine and Epidemiology, as well as the founder and director of the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at the Yale School of Medicine, discussed prior research that foregrounded the quality-of-care study as well as the current landscape of oncology care for this incarcerated or newly released population.

He began by highlighting a collaboration he is a member of, which include professionals from the Connecticut Department of Health, Department of Correction, and the COPPER Center at the Yale School of Medicine. Gross explained that this group is interested in improving outcomes among patients with cancer who are incarcerated, citing previous work showing increased risks to health-related outcomes for those who are incarcerated or newly released.

Findings from previous research conducted by this collective published in PLOS One showed that a higher risk of cancer mortality was observed among patients diagnosed during incarceration as well as during the first year following release.2 Based on these findings, Gross’s team focused on the quality of care among these patients to explore whether they were receiving guideline-concordant care.

Transcript:

I am part of a large team of collaborators and researchers that include individuals from the Connecticut Department of Health, Department of Correction, and Yale. Our group, as a whole, is interested in understanding and improving the care and outcomes of [patients] who are incarcerated, with a focus on cancer. Prior work has suggested—in general, not just cancer related—that there’s a period both during incarceration and also within the first couple of months after release when people are exposed to increased risks to their health. Sometimes, the transitions back into the community can be particularly challenging for people to get plugged into health care and the medical care that they need.

Other studies have suggested that during the time that people are incarcerated, it can be challenging to access health care. Our team’s prior work focused on overall mortality for patients who are diagnosed with cancer, and in those older studies, what we found is that patients diagnosed either while incarcerated or during the first year after release from incarceration had a higher risk of death than the general population of patients who have cancer but no history of incarceration. That led our team to dig a bit deeper into what might be the cause of these different outcomes. For this study, we focused on the quality of care people are receiving. After a diagnosis of cancer, are people getting the care that is recommended by guidelines?

References

  1. Oladeru OT, Richman IB, Aminawung JA, et al. Incarceration and quality of cancer care. JAMA Netw Open. 2025;8(10):e2537400. doi:10.1001/jamanetworkopen.2025.37400
  2. Oladeru OT, Aminawung JA, Lin HJ, et al. Incarceration status and cancer mortality: a population-based study. PLOS One. 2022;19(9):e0274703. doi:10.1371/journal.pone.0274703
Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Related Content
Advertisement

The gamma secretase inhibitor, varegacestat, conferred an 84% reduction in the risk of progression or death vs placebo among those with desmoid tumors.

Varegacestat Exhibits Improved Efficacy in Progressing Desmoid Tumors

Roman Fabbricatore
December 19th 2025
Article

The gamma secretase inhibitor, varegacestat, conferred an 84% reduction in the risk of progression or death vs placebo among those with desmoid tumors.


Why Sexual and Gender Minority Care Is an Oncologic Imperative

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.


Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.


Parkinson's disease patient, Arthritis hand, gout knee pain, or mental health care with geriatric doctor consulting examining comforting elderly senior aged adult in medical exam clinic or hospital | © Chinnapong - stock.adobe.com

How Does Decision-Making Capacity, Patient-Centered Care Inform Oncology Decisions?

Ariana Pelosci
November 25th 2025
Article

When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD; and Yesne Alici, MD, will utilize decision-making capacity techniques.


Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Related Content
Advertisement

The gamma secretase inhibitor, varegacestat, conferred an 84% reduction in the risk of progression or death vs placebo among those with desmoid tumors.

Varegacestat Exhibits Improved Efficacy in Progressing Desmoid Tumors

Roman Fabbricatore
December 19th 2025
Article

The gamma secretase inhibitor, varegacestat, conferred an 84% reduction in the risk of progression or death vs placebo among those with desmoid tumors.


Why Sexual and Gender Minority Care Is an Oncologic Imperative

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.


Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.


Parkinson's disease patient, Arthritis hand, gout knee pain, or mental health care with geriatric doctor consulting examining comforting elderly senior aged adult in medical exam clinic or hospital | © Chinnapong - stock.adobe.com

How Does Decision-Making Capacity, Patient-Centered Care Inform Oncology Decisions?

Ariana Pelosci
November 25th 2025
Article

When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD; and Yesne Alici, MD, will utilize decision-making capacity techniques.


Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.